Renaparin® Kidney Transplantation

During preservation prior to surgery, the kidney lacks natural blood flow which can lead to ischemia and when connected to the recipient blood flow, this in turn leads to ischemia-reperfusion injury (IRI). IRI poses a major challenge in many thrombotic conditions and in whole organ transplantation. According to public information, IRI results in delayed graft function in up to 40 % of transplants and may also lead to acute kidney failure. 

Due to the alarming shortage of organs available for transplantation, the prevention of IRI has become a top priority for the transplantation community. A superior treatment strategy would have the potential to extend current donor criteria, thus increasing the number of transplantable organs.

Corline’s Renaparin® is administered by flushing the vessel system of the kidney ex vivo prior to transplantation, and repairs the damaged blood vessel system. Renaparin® thus protects kidneys from the innate immune response and has been shown to significantly decrease reperfusion injury in pre-clinical models.

Corline® has been granted orphan drug designation in the EU for Renaparin™.